Lb Pharmaceuticals (LBRX) Liabilities and Shareholders Equity (2024 - 2026)

Lb Pharmaceuticals' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $393.5 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed N/A year-over-year to $393.5 million in Q1 2026; TTM through Mar 2026 was $1.0 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $312.9 million, up 833.18% from the prior year.
• Liabilities and Shareholders Equity climbed to $393.5 million in Q1 2026 per LBRX's latest filing, from $312.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $393.5 million in Q1 2026 and bottomed at $33.5 million in Q4 2024.
• The 3-year median for Liabilities and Shareholders Equity is $316.8 million (2025), against an average of $265.2 million.
• Biggest YoY gain for Liabilities and Shareholders Equity was 833.18% in 2025; the steepest drop was 833.18% in 2025.
• Year by year, Liabilities and Shareholders Equity stood at $33.5 million in 2024, then surged by 833.18% to $312.9 million in 2025, then climbed by 25.74% to $393.5 million in 2026.
• Per Business Quant, the three latest LBRX Liabilities and Shareholders Equity figures stand at $393.5 million (Q1 2026), $312.9 million (Q4 2025), and $320.7 million (Q3 2025).